BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters
30th March 2026 Uncategorised 0Promotional materials for a handful of biologics have found their way into the FDA’s hot seat.
More: BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters
Source: fierce